论文部分内容阅读
目的:探讨黛力新联合曲美布丁治疗肠易激综合征的临床疗效。方法:收集我院66例肠易激综合征患者,将其随机分为观察组和对照组,每组33例,观察组用黛力新联合盐酸曲美布丁进行治疗,对照组用曲美布丁治疗,比较两组的临床治疗效果。结果:治疗4周后,观察组总有效率为93.9%,对照组总有效率为54.5%,两组比较有显著性差异(P<0.05);两组均未出现明显不良反应。结论:黛力新联合曲美布丁治疗肠易激综合征较单独使用曲美布丁的临床疗效显著,副作用少。
Objective: To investigate the clinical efficacy of Deanxit and trimebutine in the treatment of irritable bowel syndrome. Methods: 66 patients with irritable bowel syndrome were collected and randomly divided into observation group and control group, with 33 cases in each group. The observation group was treated with dextromethorphan trimebutine hydrochloride and the control group was trimetazidine Treatment, compared the clinical treatment effect of two groups. Results: After 4 weeks of treatment, the total effective rate was 93.9% in the observation group and 54.5% in the control group, with significant difference between the two groups (P <0.05). No obvious adverse reactions were observed in both groups. Conclusion: Deanxu combined trimebutine in the treatment of irritable bowel syndrome than trimebutine alone has a significant clinical efficacy, fewer side effects.